Reconciling the Evidence on Serum Homocysteine and Ischaemic Heart Disease: A Meta-Analysis
Open Access
- 2 February 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (2), e16473
- https://doi.org/10.1371/journal.pone.0016473
Abstract
Results from genetic epidemiological studies suggest that raised serum homocysteine is a cause of ischaemic heart disease, but the results of randomised trials suggest otherwise. We aimed to update meta-analyses on each type of study using the latest published data and test a hypothesis based on antiplatelet therapy use in the trials to explain the discrepancy. Meta-analyses of ischaemic heart disease using (i) 75 studies in which the prevalence of a mutation (C T) in the MTHFR gene (which increases homocysteine) was determined in cases (22,068) and controls (23,618), and (ii) 14 randomised trials (39,597 participants) of homocysteine lowering and ischaemic heart disease events. The summary estimates from the two analyses were compared. Meta-analysis of the MTHFR studies showed a statistically significantly increased risk of ischaemic heart disease in TT compared with CC homozygotes; odds ratio 1.16 (1.04 to 1.29) for a 1.9 µmol/L homocysteine difference (TT minus CC). Meta-analysis of randomised trials showed no significant reduction in IHD risk from folic acid; relative risk 1.00 (0.93 to 1.08), despite a reduction in homocysteine of 3.3 µmol/L. There was a statistically significant difference in risk reduction between the 5 trials with the lowest prevalence of antiplatelet therapy (60% on average, usually aspirin), RR 0.93 (0.84 to 1.05) and the 5 trials with the highest prevalence (91% on average), RR 1.09 (1.00 to 1.19), p = 0.037 for the difference. Discordant results from MTHFR studies and randomised trials could be explained by aspirin reducing or negating the anti-platelet effect of lowering homocysteine. On this basis, folic acid would have a role in the primary prevention of ischaemic heart disease, when aspirin is not taken routinely, but not in secondary prevention, when it is routine.This publication has 35 references indexed in Scilit:
- Meta-Analysis of Folic Acid Supplementation Trials on Risk of Cardiovascular Disease and Risk Interaction With Baseline Homocysteine LevelsThe American Journal of Cardiology, 2010
- Homocysteine Activates Platelets In VitroClinical and Applied Thrombosis/hemostasis, 2008
- Elevated total homocysteine is associated with increased platelet activation at the site of microvascular injury: effects of folic acid administrationJournal of Thrombosis and Haemostasis, 2007
- Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidenceBMJ, 2006
- A role for PLCγ2 in platelet activation by homocysteineJournal of Cellular Biochemistry, 2006
- Homocysteine and stroke: evidence on a causal link from mendelian randomisationThe Lancet, 2005
- Relationship of homocysteine to markers of platelet and endothelial activation in ‘high risk’ hypertensives: a substudy of the Anglo-Scandinavian Cardiac Outcomes TrialInternational Journal of Cardiology, 2004
- Homocysteine, Coagulation, Platelet Function, and ThrombosisSeminars in Thrombosis and Hemostasis, 2000
- Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism.JCI Insight, 1993
- HOMOCYSTINURIA, THROMBOSIS, AND THE BLOOD-PLATELETSThe Lancet, 1964